olivLaw · US equity research
AptarGroup, Inc. ATR
Plastics Products, NEC · SIC 3089 · Vertical: Plastics Products, NEC (SIC 3089)
AptarGroup designs and makes dosing, dispensing and protection systems for pharmaceutical, fragrance, cosmetics, food, beverage and home care markets. Net sales reached 3.78 billion USD in fiscal 2025, and in the second quarter of 2026 the company passed one billion USD in quarterly sales for the first time, while margins fell under pressure from product mix and operating costs, and a new CEO took over.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, AptarGroup, Inc. (ATR) stock was 146.86 USD (+3.20% on the day), with market capitalisation 9.3 bn USD, P/E 35.6 on diluted EPS of 4.12 USD over the last 12 months, dividend yield 1.31%, beta 0.57, 52-week range 111.94–146.86 USD. Latest reported quarter (Q3 2026): revenue of 1.0 bn USD (+6.0% YoY), net income of 32.6 m USD (−74.5% YoY), diluted EPS 0.51 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 81.5
- overbought (≥ 70)
- Bollinger (20, 2)
- 112.13 – 144.04
- above the upper band · %B 1.09 · band width 24.9%
- SMA 50 / 200
- 126.44 / 127.21
- mixed trend
- MACD (12, 26, 9)
- 4.63 / 2.17
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +21.8% | −1.1% | +22.9 pp | — |
| 3 months | +7.4% | −0.5% | +7.8 pp | — |
| 6 months | +19.8% | +4.4% | +15.4 pp | — |
| Year to date | +20.4% | +12.3% | +8.1 pp | — |
| 1 year | +28.6% | +13.5% | +15.1 pp | +36.4% |
| 3 years | +17.2% | +76.4% | −59.3 pp | +49.6% |
| 5 years | +11.7% | +63.7% | −52.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 848.1 m | 887.3 m | 966.0 m | 961.1 m | 962.7 m | 982.9 m | 1.0 bn | 1.0 bn |
| Cost of revenue | 518.7 m | 550.9 m | 599.0 m | 598.0 m | 624.5 m | 631.0 m | 661.0 m | 646.2 m |
| Operating income | 120.1 m | 113.4 m | 144.4 m | 136.9 m | 106.3 m | 107.5 m | 126.7 m | 135.0 m |
| Depreciation & amortisation | 67.5 m | 65.6 m | 69.9 m | 75.2 m | 76.6 m | 75.7 m | 79.6 m | 75.5 m |
| Interest expense | 11.4 m | 11.4 m | 10.9 m | 13.5 m | 17.0 m | 16.9 m | 16.0 m | 15.8 m |
| Pre-tax income | 116.1 m | 106.0 m | 139.7 m | 154.1 m | 91.5 m | 93.8 m | 115.0 m | 60.3 m |
| Income tax | 15.2 m | 27.4 m | 28.0 m | 26.3 m | 17.3 m | 21.0 m | 27.0 m | 27.5 m |
| Net income | 100.9 m | 78.8 m | 111.7 m | 127.9 m | 74.3 m | 72.7 m | 87.6 m | 32.6 m |
| Diluted EPS | 1.48 ≈ | 1.17 | 1.67 | 1.92 | 1.13 ≈ | 1.12 | 1.36 | 0.51 |
| Operating cash flow | 178.2 m | 82.7 m | 126.0 m ≈ | 177.6 m ≈ | 183.7 m | 118.7 m | 103.5 m ≈ | 167.6 m ≈ |
| Capex | 66.1 m | 56.9 m | 63.4 m ≈ | 63.3 m ≈ | 86.8 m | 65.4 m | 57.6 m ≈ | 69.0 m ≈ |
| Dividends paid | 29.9 m | 29.9 m | 29.7 m ≈ | 29.6 m ≈ | 31.5 m | 30.9 m | 30.6 m ≈ | 30.5 m ≈ |
| Share repurchases | 37.3 m | 80.0 m | 70.0 m ≈ | 40.0 m ≈ | 175.0 m | 100.0 m | 50.0 m ≈ | 30.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 83 percentile of its own 40-quarter history (min 20.7, median 29.9, max 42.6; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8 bn | 2.9 bn | 2.9 bn | 3.2 bn | 3.3 bn | 3.5 bn | 3.6 bn | 3.8 bn |
| Revenue YoY | +12.0% | +3.4% | +2.4% | +10.2% | +2.9% | +5.0% | +2.7% | +5.4% |
| Net income | 194.8 m | 242.2 m | 214.0 m | 244.1 m | 239.3 m | 284.5 m | 374.5 m | 392.8 m |
| Net income YoY | −11.5% | +24.4% | −11.6% | +14.0% | −2.0% | +18.9% | +31.7% | +4.9% |
| Diluted EPS | 3.00 | 3.66 | 3.21 | 3.61 | 3.59 | 4.25 | 5.53 | 5.89 |
| Diluted EPS YoY | −12.0% | +22.0% | −12.3% | +12.5% | −0.6% | +18.4% | +30.1% | +6.5% |
| net % | 7.0% | 8.5% | 7.3% | 7.6% | 7.2% | 8.2% | 10.5% | 10.4% |
| Free cash flow | 102.4 m | 272.2 m | 324.2 m | 55.5 m | 168.2 m | 262.9 m | 366.9 m | 299.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 402.4 m USD
- Financial debt
- 183.9 m USD
- Net debt
- -218.5 m USD
- Equity
- 2.7 bn USD
- Total assets
- 5.3 bn USD
- Debt / equity
- 0.07x
- Current ratio
- 1.62x
- ROE
- 15.2%
- ROA
- 8.1%
- FCF margin
- 7.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 2.9 bn | 3.2 bn | 3.3 bn | 3.5 bn | 3.6 bn | 3.8 bn | SEC (XBRL)· 06 Feb 2026verified |
| Cost of revenue | — | — | — | 2.2 bn | 2.2 bn | 2.4 bn | SEC (XBRL)· 06 Feb 2026verified |
| Gross profit | 906.0 m | — | — | 1.3 bn ≈ | 1.4 bn ≈ | 1.4 bn ≈ | SEC (XBRL)· 06 Feb 2026derived |
| Research & development | 92.5 m | 99.8 m | 93.5 m | 92.8 m | 96.1 m | 105.1 m | SEC (XBRL)· 06 Feb 2026verified |
| Operating income | 339.5 m | 347.3 m | 379.3 m | 404.0 m | 496.5 m | 501.0 m | SEC (XBRL)· 06 Feb 2026verified |
| Depreciation & amortisation | 220.3 m | 234.9 m | 233.7 m | 248.6 m | 263.8 m | 287.4 m | SEC (XBRL)· 06 Feb 2026verified |
| EBITDA | 559.8 m ≈ | 582.2 m ≈ | 613.0 m ≈ | 652.6 m ≈ | 760.3 m ≈ | 788.4 m ≈ | SEC (XBRL)· 06 Feb 2026derived |
| Interest expense | 33.2 m | 30.3 m | 40.8 m | 40.4 m | 43.9 m | 52.7 m | SEC (XBRL)· 06 Feb 2026verified |
| Pre-tax income | 301.2 m | 321.7 m | 334.7 m | 374.8 m | 469.8 m | 491.4 m | SEC (XBRL)· 06 Feb 2026verified |
| Income tax | 87.1 m | 78.0 m | 95.1 m | 90.6 m | 95.6 m | 98.9 m | SEC (XBRL)· 06 Feb 2026verified |
| Net income | 214.0 m | 244.1 m | 239.3 m | 284.5 m | 374.5 m | 392.8 m | SEC (XBRL)· 06 Feb 2026verified |
| Diluted EPS | 3.21 | 3.61 | 3.59 | 4.25 | 5.53 | 5.89 | SEC (XBRL)· 06 Feb 2026verified |
| Weighted average diluted shares | 66.7 m | 67.7 m | 66.7 m | 66.9 m | 67.7 m | 66.7 m | SEC (XBRL)· 06 Feb 2026verified |
| Dividend per share | 1.44 | 1.50 | 1.52 | 1.58 | 1.72 | 1.83 | SEC (XBRL)· 06 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 300.1 m | 122.9 m | 141.7 m | 223.6 m | 223.8 m | 402.4 m | SEC (XBRL)· 06 Feb 2026verified |
| Inventories | 379.4 m | 441.5 m | 486.8 m | 513.1 m | 461.8 m | 537.8 m | SEC (XBRL)· 06 Feb 2026verified |
| Current assets | 1.4 bn | 1.4 bn | 1.4 bn | 1.5 bn | 1.5 bn | 1.9 bn | SEC (XBRL)· 06 Feb 2026verified |
| Property, plant & equipment, net | 1.2 bn | 1.3 bn | 1.3 bn | 1.5 bn | 1.4 bn | 1.7 bn | SEC (XBRL)· 06 Feb 2026verified |
| Goodwill | 898.5 m | 974.2 m | 945.6 m | 963.4 m | 936.3 m | 1.1 bn | SEC (XBRL)· 06 Feb 2026verified |
| Intangibles (excl. goodwill) | 344.3 m | 362.3 m | 315.7 m | 283.2 m | 254.8 m | 255.3 m | SEC (XBRL)· 06 Feb 2026verified |
| Total assets | 4.0 bn | 4.1 bn | 4.2 bn | 4.5 bn | 4.4 bn | 5.3 bn | SEC (XBRL)· 06 Feb 2026verified |
| Short-term debt | 52.2 m | 147.3 m | 3.8 m | 81.8 m | 176.0 m | 183.9 m | SEC (XBRL)· 06 Feb 2026verified |
| Current liabilities | 780.3 m | 982.5 m | 917.2 m | 1.3 bn | 1.1 bn | 1.2 bn | SEC (XBRL)· 06 Feb 2026verified |
| Equity | 1.9 bn | 2.0 bn | 2.1 bn | 2.3 bn | 2.5 bn | 2.7 bn | SEC (XBRL)· 06 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 570.2 m | 363.4 m | 478.6 m | 575.2 m | 643.4 m | 570.0 m | SEC (XBRL)· 06 Feb 2026verified |
| Capex | 246.0 m | 307.9 m | 310.4 m | 312.3 m | 276.5 m | 270.4 m | SEC (XBRL)· 06 Feb 2026verified |
| Free cash flow | 324.2 m ≈ | 55.5 m ≈ | 168.2 m ≈ | 262.9 m ≈ | 366.9 m ≈ | 299.6 m ≈ | SEC (XBRL)· 06 Feb 2026derived |
| Investing cash flow | -452.0 m | -457.2 m | -295.6 m | -324.5 m | -396.7 m | -331.4 m | SEC (XBRL)· 06 Feb 2026verified |
| Financing cash flow | -73.7 m | -81.5 m | -162.1 m | -171.6 m | -225.3 m | -77.5 m | SEC (XBRL)· 06 Feb 2026verified |
| Dividends paid | 92.7 m | 98.5 m | 99.5 m | 103.7 m | 114.1 m | 120.8 m | SEC (XBRL)· 06 Feb 2026verified |
| Share repurchases | 0 | 78.1 m | 92.1 m | 47.6 m | 68.6 m | 365.0 m | SEC (XBRL)· 06 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 69 / 100
A scoring methodology on indicators and valuation, not investment advice.
(margin_of_safety <= -0.25 & agreement in ['high', 'medium'])
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 9.3 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation57
- Returns84
- Quality73
- Balance sheet74
- Growth68
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 24.05 – 172.15 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)71.55 – 109.58 (Mid 86.33)WACC 9.2% · starting FCFF 343.5 m USD · terminal value share of EV 73%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): 29.7%
- Peers: EV/EBITDA155.42 – 172.15 (Mid 167.51)6 companies used · median multiple 13.6x · quartiles 12.6x – 14.0xAWI, CMT, KRT, MYE, NWL, SWIM
- Peers: P/E88.45 – 107.63 (Mid 96.75)5 companies used · median multiple 23.5x · quartiles 21.5x – 26.1xAWI, CMT, DSWL, KRT, MYE
- Dividend discount (DDM)24.05 – 32.34 (Mid 27.58)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Unattractive profile · Score 69/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 12.7% | 71 (vs peers) | 10% |
| Net margin · Quality | 6.7% | 50 (vs peers) | 6% |
| FCF conversion · Quality | 110.3% | 100 (on a fixed band) | 6% |
| Revenue CAGR 3Y · Growth | 4.4% | 36 (on a fixed band) | 8% |
| EPS CAGR 3Y · Growth | 17.9% | 100 (on a fixed band) | 8% |
| Net debt / EBITDA · Balance sheet | 0.0x | 71 (vs peers) | 10% |
| Interest coverage · Balance sheet | 7.2x | 88 (on a fixed band) | 6% |
| Current ratio · Balance sheet | 1.5x | 59 (on a fixed band) | 4% |
| P/E (TTM) · Valuation | 35.6x | 43 (vs peers) | 10% |
| EV/EBITDA · Valuation | 11.9x | 86 (vs peers) | 10% |
| FCF yield · Valuation | 3.2% | 40 (on a fixed band) | 8% |
| Shareholder yield (distributions) · Returns | 5.1% | 73 (on a fixed band) | 6% |
| Payout ratio (FCF) · Returns | 41.9% | 100 (on a fixed band) | 4% |
Score groups
- Balance sheet74/100 · 3/3 factors with a value
- Growth68/100 · 2/2 factors with a value
- Quality73/100 · 3/3 factors with a value
- Returns84/100 · 2/2 factors with a value
- Valuation57/100 · 3/3 factors with a value
Memo
AptarGroup, Inc (ATR). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 3.8 bn USD in 2025; YoY growth 5.4%; net margin 6.7%; ROE 9.9%; net debt/EBITDA 0.0x.
The estimated value range is 80.00–108.61 USD per share (median of 4 methods, agreement: medium); assumptions are illustrative. Against the central value of 91.54 USD, the price of 146.86 USD leaves a potential of -37.7% (value / price − 1) and a margin of safety of -60.4% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 69/100, methodological classification: unattractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 12.7%
- FCF conversion: 110.3%
- EPS CAGR 3Y: 17.9%
- Net debt / EBITDA: 0.0x
- Interest coverage: 7.2x
- EV/EBITDA: 11.9x
- Shareholder yield (distributions): 5.1%
- Payout ratio (FCF): 41.9%
What contradicts it
- The price is above the estimated value range
Versus the vertical median
Plastics Products, NEC (SIC 3089) · same industry (4-digit SIC) · compared with 8 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ENTGEntegris, Inc. | 21.8 bn | 55.7 | 9.6% | 11.1% | −1.4% | +85% / +37% |
| ATRAptarGroup, Inc | 9.3 bn | 35.6 | 9.9% | 6.7% | +5.4% | +29% / +17% |
| AWIArmstrong World Industries, Inc. | 7.4 bn | 23.5 | 36.0% | 18.4% | +12.1% | −7% / +107% |
| NWLNewell Brands Inc | 2.5 bn | — | -12.8% | -4.4% | −5.0% | +61% / −23% |
| MYEMyers Industries, Inc. | 1.1 bn | 37.6 | 9.7% | 3.3% | −1.3% | +58% / +62% |
| KRTKarat Packaging Inc. | 1.1 bn | 21.5 | 31.2% | 10.2% | +10.7% | +143% / +149% |
| SWIMLatham Group, Inc. | 963.2 m | 100.2 | 2.2% | 1.6% | +7.4% | +14% / +262% |
| CMTCore Molding Technologies, Inc. | 187.1 m | 26.1 | 4.4% | 2.4% | −9.5% | +12% / +18% |
| DSWLDeswell Industries, Inc. | 46.5 m | 4.4 | 10.0% | 17.3% | −9.3% | −19% / +12% |
1- and 3-year price returns: for ATR from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 88.69 Total return -39% · Per year -39% | 156.81 Total return 8% · Per year 8% | 236.22 Total return 63% · Per year 63% |
| 3 years | 85.85 Total return -38% · Per year -15% | 170.82 Total return 21% · Per year 6% | 282.56 Total return 98% · Per year 26% |
| 5 years | 83.11 Total return -38% · Per year -9% | 186.08 Total return 34% · Per year 6% | 338.00 Total return 140% · Per year 19% |
- Exit P/E± 42.70
- Net margin± 29.89
- Annual revenue growth± 24.57
- Annual dilution± 2.51
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 31 Jul 2026; since then the company filed 10-Q (30 Oct 2026), 8-K (29 Oct 2026 · results).
In brief
AptarGroup designs and makes dosing, dispensing and protection systems for pharmaceutical, fragrance, cosmetics, food, beverage and home care markets. Net sales reached 3.78 billion USD in fiscal 2025, and in the second quarter of 2026 the company passed one billion USD in quarterly sales for the first time, while margins fell under pressure from product mix and operating costs, and a new CEO took over.
SWOT
Strengths
- Global leadership in dosing and protection technologies, with a diversified portfolio across many end markets 1.
- A broad customer base with no single dependence reduces concentration risk 1.
- A balance sheet described by management as strong, with cash returned through dividends and share repurchases 3.
Weaknesses
Opportunities
Risks
- Tariffs and trade restrictionshigh
Tariffs imposed by the United States and countermeasures by other countries could raise costs and make price increases necessary 1.
- Plant disruptionshigh
A material failure at one of the plants could affect deliveries and customer relations, especially in clean room operations 1.
- Single source supplymedium
Some resins and components for Pharma come from a single source, and interruptions could affect deliveries 1.
- Fixed costs and utilisationmedium
When demand falls, unused capacity is charged directly to cost of sales, which can reduce margins 1.
- Cybersecuritymedium
Cyberattacks or IT system failures could compromise data and operations, with effects on reputation 1.
Investment thesis
What would need to be true (bull case)
- If demand for injectables and pharmaceutical dispensing stays strong, the Pharma segment could support margins over the medium term 23.
- If mix pressures and operating inefficiencies ease, margins could recover in line with management's expectations 3.
- A diversified portfolio and a solid balance sheet could support dividends and buybacks if operating performance improves 13.
What would break the thesis
- If margins do not recover, profitability pressure could continue, mainly because of less profitable product mix 2.
- Tariffs and countermeasures could reduce demand and raise costs, while core growth remains modest 13.
- The change of leadership and intensifying competition could complicate execution of the strategy in the near term 13.
What to watch
- Evolution of the adjusted EBITDA margin and recovery of Pharma product mixQ3 2026
- Delivery against the adjusted EPS guidance range for the third quarter of 2026Q3 2026
- End of the emergency medicine destocking effect in PharmaQ4 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 31 Jul 2026; since then the company filed 10-Q (30 Oct 2026), 8-K (29 Oct 2026 · results).
The business
Aptar's strategy centers on profitable organic growth, especially in high growth regions, managing fixed costs through Global Business Service Centers, improving return on invested capital, and pursuing acquisitions and partnerships that extend technology platforms and geographic reach 1.
Segments
Market context
End markets are diverse, spanning pharmaceutical, fragrance, facial skincare, colour cosmetics, food, beverage, personal care and home care 1. Pharmaceutical demand is supported by the preference for convenient dosing, while consumer markets continue to shift from non-dispensing to dispensing formats 1. Growth remains moderate, and exposure to consumer spending could keep results below expectations if economic conditions weaken 1.
Trends
- Shift to dispensing formatstailwind
Consumers and patients increasingly prefer dispensing formats, which supports demand for pumps and dispensing closures 1.
- Sustainability and reusemixed
Customers ask for refillable and recyclable solutions, and the move to all-plastic pumps and recycled resins could open product opportunities 1.
- Tariffs and input costsheadwind
Tariffs imposed in 2025 raised the cost of some raw materials and components, and the company could be forced to raise prices if tariffs widen 1.
- Higher value productstailwind
Higher value products such as coated injectable components and GLP-1 related solutions supported sales in the first half of 2026 2.
Competitive position
Aptar says its markets are highly competitive, with private and public competitors from regional to international scale becoming increasingly credible 1. Competition could reduce market share if the company fails to introduce new products or more sustainable solutions quickly 1.
- Regional and international competitors not named in the source
The filings do not name direct competitors and refer only to private and public entities of regional and international reach 1.
- Pharma pump and valve makers
Competition in the pharmaceutical segment is described generically without naming companies in the annual report 1.
- Beverage and food closure suppliers
In Closures competition comes from regional and international suppliers, not identified in the source 1.
- Beauty packaging suppliers
In Beauty competition exists across all product lines, but the sources do not indicate specific companies 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- «Логика молока» получила в управление завод упаковки AptarGroupKommersant (RU) · 21 Sept 2026 · RU
- Putin puts U.S.-based packaging company AptarGroup’s Russian factory under temporary management by Danone’s former Russian armMeduza English (independent RU/exile) · 21 Sept 2026 · EN
- Российская "дочка" производителя упаковки Aptar передана в управление H&NInterfax Russia (RU) · 21 Sept 2026 · RU
The latest news item in our archive is from 21 Sept 2026; the newest SEC filing is from 30 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report30 Oct 2026
- Current report29 Oct 2026Results of operations · Financial statements and exhibits
- Current report21 Sept 2026Regulation FD disclosure
- Current report10 Sept 2026Departure or appointment of officers
- Current report01 Sept 2026Departure or appointment of officers
- Quarterly report31 Jul 2026
- Current report30 Jul 2026Results of operations · Financial statements and exhibits
- Current report13 May 2026Departure or appointment of officers
- Current report07 May 2026Shareholder vote
- Quarterly report01 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / AptarGroup, Inc. · 06 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / AptarGroup, Inc. · 31 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / AptarGroup, Inc. · 30 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.